3. Main characteristics of included studies.

Study	Number randomised	Alzheimer’s disease severity/ Mean MMSE (SD)	Mean age (SD)	Mean BMI (SD)	Use of AD medication	Treatment duration	Oucomes relevant to this review
Souvenir II Europe	Total 259 IG 130 CG 129	very mild IG 24.9 (2.9) CG 25.0 (2.8)	IG 74.4 (6.9) CG 73.2 (8.4)	IG 26.1 (4.1) CG 26.7 (4.2)	No	24 weeks	NTB memory function NTB executive function Modified NTB composite score DAD Tolerance and safety
S‐connect USA	Total 527 IG 265 CG 262	mild‐to‐moderate IG 19.5 (3.2) CG 19.4 (3.0)	IG 76.6 (8.2) CG 76.9 (8.2)	IG 26.2 (4.2) CG 26.6 (4.6)	AChEI: 34% Memantine: 6% Combined: 60%	24 weeks	ADAS‐cog Cognitive test battery CDR SoB MMSE ADCS‐ADL Tolerance and safety
LIPIDIDIET Europe	Total 311 IG 153 CG 158	prodromal IG 26.4 (2.1) CG 26.9 (1.9)	IG 71.3 (7.0) CG 70.7 (6.2)	not reported	No	24 months	NTB Cognitive function (modified version) NTB memory function NTB executive function Progression to dementia CDR SoB Tolerance and safety

AChEI: acetylcholinesterase inhibitors; AD: Alzheimer's disease; ADAS‐Cog: Alzheimer's Disease Assessment Scale ‐ Cognitive subscale; ADCS‐ADL: Alzheimer's Disease Cooperative Study ‐ Activities of Daily Living; BMI: body mass index; CDR‐SOB: Clinical Dementia Rating ‐ Sum of Boxes; CG: control group; DAD: Disability Assessment for Dementia; IG: intervention group; MMSE: Mini‐Mental State Examination; NTB: neuropsychological test battery; PP: per protocol; SD: standard deviation.